GlassScriptPhysician profile
Linda J Fields
NPI 1144226432
$4,200.64
in general payments reported to CMS, 2019-2025
24 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $53.63 · 2021: $211 · 2022: $596 · 2023: $664 · 2024: $657 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,212.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.37 | 2020-2025 | |
| Janssen Biotech, INC. | $904.29 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $480.64 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.21 | 2021-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $214.03 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $206.04 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $152.21 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $73.95 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $69.09 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $67.40 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $65.74 | 2021-2024 | Ocaliva |
| Ucb, INC. | $65.01 | 2019 | |
| Lilly USA, LLC | $52.69 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $49.75 | 2019-2022 | |
| Madrigal Pharmaceuticals | $36.83 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.27 | 2025 | Wegovy |
| Celltrion USA INC. | $27.99 | 2025 | Vegzelma |
| Blueprint Medicines Corporation | $24.56 | 2025 | Ayvakit |
| Genzyme Corporation | $22.81 | 2023 | |
| Medtronic, INC. | $21.89 | 2024 | Gi Genius |
| Pacira Pharmaceuticals Incorporated | $18.85 | 2019 | |
| Celgene Corporation | $13.88 | 2021 | |
| Pfizer INC. | $12.80 | 2021 | |
| Shionogi INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.